T. Rowe Price Associates
IMGN

T. Rowe Price Associates’s Immunogen Inc IMGN Stock Holding History

T. Rowe Price Associates’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,088,213
Closed -$32.3M – 3005
2023
Q4 		$32.3M Sell
1,088,213
-2,818,157
-72% -$56.1M ﹤0.01% 829
2023
Q3 		$62M Buy
3,906,370
+1,584,109
+68% +$26.3M 0.01% 619
2023
Q2 		$43.8M Buy
2,322,261
+2,208,333
+1,938% +$26.1M 0.01% 742
2023
Q1 		$438K Buy
113,928
+8,878
+8% +$37.8K ﹤0.01% 2168
2022
Q4 		$521K Buy
105,050
+4,227
+4% +$22.9K ﹤0.01% 2112
2022
Q3 		$482K Buy
100,823
+52,410
+108% +$276K ﹤0.01% 2143
2022
Q2 		$218K Buy
48,413
+1,420
+3% +$6.17K ﹤0.01% 2569
2022
Q1 		$224K Buy
46,993
+10,920
+30% +$60.5K ﹤0.01% 2673
2021
Q4 		$268K Sell
36,073
-51,615
-59% -$321K ﹤0.01% 2643
2021
Q3 		$497K Buy
87,688
+786
+0.9% +$4.54K ﹤0.01% 2388
2021
Q2 		$573K Buy
86,902
+3,116
+4% +$21.7K ﹤0.01% 2327
2021
Q1 		$679K Buy
83,786
+9,194
+12% +$75.1K ﹤0.01% 2226
2020
Q4 		$481K Buy
74,592
+62,217
+503% +$363K ﹤0.01% 2260
2020
Q3 		$45K Hold
12,375
– – ﹤0.01% 2553
2020
Q2 		$57K Buy
12,375
+1,002
+9% +$4.26K ﹤0.01% 2458
2020
Q1 		$39K Buy
+11,373
New +$49.7K ﹤0.01% 2468
2019
Q4 		– Sell
-1,010,498
Closed -$2.44M – 2559
2019
Q3 		$2.44M Buy
1,010,498
+135,008
+15% +$358K ﹤0.01% 1529
2019
Q2 		$1.9M Sell
875,490
-1,565,274
-64% -$3.7M ﹤0.01% 1609
2019
Q1 		$6.61M Buy
2,440,764
+103,471
+4% +$448K ﹤0.01% 1369
2018
Q4 		$11.2M Buy
2,337,293
+66,546
+3% +$404K ﹤0.01% 1292
2018
Q3 		$21.5M Sell
2,270,747
-628,364
-22% -$6.04M ﹤0.01% 1206
2018
Q2 		$28.2M Buy
2,899,111
+689,998
+31% +$7.27M ﹤0.01% 1081
2018
Q1 		$23.2M Buy
2,209,113
+233,397
+12% +$2.31M ﹤0.01% 1138
2017
Q4 		$12.7M Buy
1,975,716
+1,040,580
+111% +$6.42M ﹤0.01% 1296
2017
Q3 		$7.15M Buy
935,136
+907,500
+3,284% +$6.03M ﹤0.01% 1390
2017
Q2 		$196K Buy
27,636
+36
+0.1% +$165 ﹤0.01% 2389
2017
Q1 		$107K Hold
27,600
– – ﹤0.01% 2482
2016
Q4 		$56K Sell
27,600
-46,600
-63% -$93.6K ﹤0.01% 2515
2016
Q3 		$199K Hold
74,200
– – ﹤0.01% 2357
2016
Q2 		$229K Buy
74,200
+31,700
+75% +$199K ﹤0.01% 2274
2016
Q1 		$362K Hold
42,500
– – ﹤0.01% 2094
2015
Q4 		$577K Buy
42,500
+15,100
+55% +$186K ﹤0.01% 1897
2015
Q3 		$263K Sell
27,400
-5,000
-15% -$73.1K ﹤0.01% 2186
2015
Q2 		$466K Hold
32,400
– – ﹤0.01% 2029
2015
Q1 		$290K Sell
32,400
-1,013
-3% -$7.34K ﹤0.01% 2209
2014
Q4 		$204K Buy
33,413
+3,213
+11% +$29.4K ﹤0.01% 2347
2014
Q3 		$320K Hold
30,200
– – ﹤0.01% 2131
2014
Q2 		$358K Buy
30,200
+8,900
+42% +$112K ﹤0.01% 2102
2014
Q1 		$318K Hold
21,300
– – ﹤0.01% 2129
2013
Q4 		$312K Hold
21,300
– – ﹤0.01% 2127
2013
Q3 		$363K Buy
+21,300
New +$374K ﹤0.01% 2018

Other funds holding IMGN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

T. Rowe Price Associates's IMGN Position: Q1 2024 in Review

T. Rowe Price Associates sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 1,088,213 shares — an estimated $32.3M sold.

T. Rowe Price Associates first reported a position in IMGN in Q3 2013 and held it in 41 quarters. The position peaked at $62M in Q3 2023. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.

  • T. Rowe Price Associates reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,088,213 Immunogen Inc shares in Q1 2024, an estimated $32.3M.
  • T. Rowe Price Associates first reported a position in Immunogen Inc in Q3 2013 and held it in 41 quarters.
  • T. Rowe Price Associates's Immunogen Inc position peaked at $62M in Q3 2023.
  • 3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.

Based on T. Rowe Price Associates's 13F filing for Q1 2024, filed 15 May 2024.